MNPR - Monopar Therapeutics
49.89
1.100 2.205%
Share volume: 969
Last Updated: Wed 05 Feb 2025 05:29:31 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.31%
PREVIOUS CLOSE
CHG
CHG%
$48.79
1.10
2.25%
Fundamental analysis
31%
Profitability
35%
Dept financing
5%
Liquidity
50%
Performance
30%
Performance
5 Days
9.24%
1 Month
103.39%
3 Months
204.76%
6 Months
7,768.85%
1 Year
13,375.58%
2 Year
1,218.68%
Key data
Stock price
$49.89
DAY RANGE
$47.61 - $51.88
52 WEEK RANGE
$0.32 - $49.98
52 WEEK CHANGE
$15,378.88
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Chandler D. Robinson
Region: US
Website: monopartx.com
Employees: 10
IPO year: 2019
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: monopartx.com
Employees: 10
IPO year: 2019
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Monopar Therapeutics Inc. engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.
Recent news